Compare MTC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTC | ZVRA |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.2M | 741.9M |
| IPO Year | 2018 | 2015 |
| Metric | MTC | ZVRA |
|---|---|---|
| Price | $3.14 | $12.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 105.6K | ★ 2.0M |
| Earning Date | 12-13-2024 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $21.03 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $0.25 | $7.16 |
| 52 Week High | $9.10 | $14.27 |
| Indicator | MTC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 61.71 |
| Support Level | $2.37 | $8.26 |
| Resistance Level | $3.49 | $14.27 |
| Average True Range (ATR) | 0.62 | 0.76 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 16.02 | 64.62 |
MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. The company offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future and HC Securities, and MM Global. The Gujia segment provides market data services and consulting services to customers in China; and MM Global segment operates as an introducing broker that clears all transactions through a clearing broker dealer and earns commission income.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.